Serum NF-κBp65, TLR4 as Biomarker for Diagnosis of Preeclampsia

The aim of this study was to evaluate the serum NF-κBp65, TLR4 (Toll-like receptor 4) expression in patients of preeclampsia and its diagnostic value as biomarkers.

Thirty patients with preeclampsia (case group) and 30 normal pregnant women (control group) were included in this study. The serum level of NF-κBp65 and TLR4 were examined by enzyme linked immunosorbent assay (ELISA), and compared between the two groups. The diagnostic sensitivity, specificity and area under the receiver operating characteristic (ROC) curve were calculated by STATA11.0 statistical software.

The expression level of TLR4 and NF-κBp65 in serum of preeclampsia patient group was 3.76±1.07ng/ ml and 183.20±49.19ng/ml, whereas that in the serum of the normal pregnant group was 2.43±0.69ng/ml and 98.68±29.80ng/ml. The expression of TLR4 and NF-κBp65 in serum of preeclampsia patient group was significantly higher than that of the normal pregnant group (P<0.05); The Pearson correlation test showed that the TLR4 expression in the serum of preeclampsia patients and normal pregnant women was positively correlated with their NF-κBp65 expression [r_preeclampsia=0.46, (P<0.05), r_normal=0.48, (P<0.05)]. When TLR4 and NF-κBp65 were selected as the reference indexes, the diagnostic sensitivity of preeclampsia was 86.67% (95%CI:69.28%-96.24%) and 90.33% (95%CI:73.47%-97.89%), and the specific ity was 70.00% (95%CI:50.60%-85.27%) and 83.33% (95%CI:65.28%-94.36%). The area under the ROC curve was 0.84 and 0.89.

Serum levels of TLR4 and NF-κBp65 was significantly higher in patients with preeclampsia which may involve in the pathogenesis of preeclampsia, and can be used as biomarker for predicting preeclampsia.